13,653 views
Parkinson's disease and innovations in clinical trials. We discuss this with Alessandro Tessitore, professor of Neurology at the University of Campania "Luigi Vanvitelli" and member of the LIMPE–DISMOV Academy, a leading scientific society for the study of Parkinson's disease and movement disorders. PARKINSON'S DISEASE AND CLINICAL TRIALS The diagnosis of Parkinson's disease and Parkinsonisms is a clinical diagnosis that sometimes, in a significant number, requires confirmation through the use of biomarkers. Magnetic Resonance and Molecular Imaging biomarkers are currently among the emerging biomarkers in the scenario of Parkinson's disease and Parkinsonisms. What is the role of these markers? They play a role in the mechanism and determinism of the onset of the disease, in monitoring the follow-up, in the progression of the disease and in some cases also in therapy as therapeutic biomarkers. What does clinical trials in this field consist of? The diagnosis of Parkinson's disease affects people differently. In some, it may give rise to the desire to be involved in a clinical trial, to participate. It is the best way to fight the disease, promoting the development of new treatments that can slow its progression or stop it. Not all studies test drugs. Many simply collect data and samples to better understand the biological functioning of the disease. In some clinical trials, different activities are evaluated, such as: physical activity, physiotherapy to which one can undergo or other non-invasive treatments that do not involve the use of drugs. ___________________ To learn more about this and other topics, visit Medical Excellence TV: https://www.medicalexcellencetv.it/ma...